Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + cisplatin + fluorouracil
- Development stage
- Unknown
- Lead developer
- National Taiwan University Hospital
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
BPF-CCRT is a neoadjuvant combination treatment regimen consisting of bevacizumab, a humanized monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A), administered concurrently with platinum-based chemotherapy (typically cisplatin), 5-fluorouracil (5-FU), and radiation therapy. This regimen was specifically investigated by National Taiwan University Hospital in a Phase 2 clinical trial for patients with locally advanced (Stage III) esophageal squamous cell carcinoma (ESCC). The therapeutic rationale is to inhibit tumor angiogenesis via bevacizumab while utilizing the cytotoxic and radiosensitizing properties of the PF-CCRT backbone to improve pathological complete response rates and overall survival in a patient population where high VEGF-A expression is linked to poor prognosis.
- Other names
- bevacizumab plus PF-CCRTbevacizumab + cisplatin + 5-fluorouracil + radiation
02
Targets
Beyond the preview
Go deeper on bevacizumab + cisplatin + fluorouracil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + cisplatin + fluorouracil.